Tag:
Javelin Pharmaceuticals
Latest Headlines
Latest Headlines
Javelin and Myriad terminate merger pact
Javelin Pharmaceuticals and Myriad Pharmaceuticals have officially terminated their merger pact, clearing the way for Javelin to accept Hospira's $141 million buyout offer. Hospira's offer was
Javelin jilts Myriad in favor of Hospira's $141M takeover offer
Javelin Pharmaceuticals is dumping Myriad Pharmaceuticals and its $81 million takeover deal in exchange for a much, much better deal from Hospira. Javelin shares skyrocketed 63 percent this morning
Myriad grabs pain drug in $91M Javelin buyout
Myriad Pharmaceuticals has snared Javelin Pharmaceuticals and its promising post-operative pain drug Dyloject in an all-stock deal initially valued at $91 million. Javelin (JAV) shareholders will
Javelin shares tank on mixed pain data
Shares of Javelin Pharmaceuticals tanked Tuesday morning after investors got wind of mixed Phase III data for its post-operative pain drug Ereska. Its stock plunged 30 percent on the news that Ereska
Javelin cuts jobs by 15%
This was certainly a week for layoff news . Today's offering is from Cambridge, MA-based Javelin Pharmaceuticals, which is reducing its workforce by 15 percent. The company had 44 full-time employees
